Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321100 · ClinicalTrials.gov registry record · Phase 2
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00321100 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 23 participants.
The verdict
NCT00321100, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the objective response rate of patients with previously untreated metastatic colorectal cancer treated with the combination of cetuximab, capecitabine, and oxaliplatin with out without bevacizumab.
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG cetuximab
- DRUG bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-04-12 |
| Est. Completion | 2013-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321100
The ClinicalTrials.gov registry entry for NCT00321100 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Capecitabine is the first listed.
NCT00321100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321100 about?
NCT00321100 is a clinical study titled "Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab". The purpose of this study is to determine the objective response rate of patients with previously untreated metastatic colorectal cancer treated with the combination of cetuximab, capecitabine, and oxaliplatin with out without bevacizumab.
What is the current status of trial NCT00321100?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2006-04-12. Estimated completion is 2013-12-18.
What interventions are being tested in trial NCT00321100?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), cetuximab (DRUG), bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00321100?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.